Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

Phase 2 Completed 120 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of idarubicin and cladribine in treating children who have recurrent acute myeloid leukemia.

Timeline

Start: 1998-03
Primary completion: 2004-12
Completion: 2007-03

Publications

Results Chaleff S, Hurwitz CA, Chang M, Dahl G, Alonzo TA, Weinstein H. Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study. Br J Haematol. 2012 Mar;156(5):649-55. doi: 10.1111/j.1365-2141.2011.08976.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cladribine	Small molecule	8 mg/m2	Intravenous
Subject	Idarubicin	Small molecule	10 mg/m2	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications